Insight on Alteogen’s non-exclusive licensing deal for ALT-B4 to a top 10 global pharma
South Korean company Alteogen Inc. signed a nonexclusive global license agreement with a top 10 global pharmaceutical company for its recombinant human... Read More
Clovis in-licensing deal for cancer program from 3B Pharmaceuticals
Clovis Oncology inks an agreement with privately held 3B Pharmaceuticals GmbH for global rights (ex. Europe, Russia, Turkey and Israel) to a... Read More
Alexion’s inlicensing deal for Amyloidosis Candidate In Japan
Posted on12 Sep 2019
Comments0
Alexion Pharmaceuticals announced a license agreement with BridgeBio Pharma’s subsidiary Eidos Therapeutics. Per the terms of the deal, Alexion will obtain an... Read More
Glenmark Specialty S.A’s exclusive licensing agreement with Grandpharma (China) Co. Ltd for commercializing Ryaltris in China
Posted on07 Feb 2019
TagsGlemark outlicensing, global pharma licensing deal, licensing deal in pharma, outlicensing in pharma
Comments0
Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, announced that its Swiss subsidiary, Glenmark Specialty S.A, has entered into an exclusive... Read More
Insight on Daiichi Sankyo’s ROS1/NTRK inhibitor DS-6051 licensing deal with AnHeart Therapeutics
Daiichi Sankyo and AnHeart Therapeutics announced they have entered into a worldwide exclusive license agreement for DS-6051, Daiichi Sankyo’s selective ROS1/NTRK inhibitor,... Read More
2018 Pharma Deal: Sanofi’s agreement to buy Bioverati @ $10.9 billion
Posted on18 Dec 2018
TagsBioverati, global pharma deals, global pharma licensing deal, pharma acquisition, pharma deal, Sanofi
Comments0
Sanofi and Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have entered into a definitive... Read More
2018 Pharma Deal: Novartis’ acquisition of AveXis: $8.1 billion
Posted on18 Dec 2018
TagsAveXis, global pharma deals, global pharma licensing deal, novartis, pharma acquisition, pharma deal
Comments0
Novartis has agreed to acquire the US-based Nasdaq-listed clinical stage gene therapy company for USD 218 per share or a total of... Read More
Pharma aaquisition: Aurobindo to acquire dermatology and oral solids businesses from Sandoz Inc. for $900 million
Aurobindo Pharma’s US based subsidiary Aurobindo Pharma USA Inc has entered into a definitive agreement with Sandoz Inc., USA, a Novartis division,... Read More
Case Study: Novartis Pharma’s global licensing deal to develop & commercialise MOR106
MOR106 is an investigational, fully human, IgG1 monoclonal antibody directed against the target IL-17C that was generated in a collaboration between MorphoSys... Read More
Licensing Case Study: Nuvo Ireland’s acquisition of US rights for Resultz from Piedmont Pharma
Posted on17 Jan 2018
Comments0
Nuvo Pharmaceuticals Inc. (Nuvo), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, announced that its wholly... Read More